ABCL – abcellera biologics inc. - common shares (US:NASDAQ)

News

AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 [Yahoo! Finance]
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause [Yahoo! Finance]
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
AbCellera Biologics (NASDAQ:ABCL) was upgraded by analysts at Wall Stree
AbCellera Biologics (NASDAQ:ABCL) was downgraded by analysts at Wall Str
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com